These findings suggest that the activation of EGFR signaling promotes the osteolytic invasion and metastasis of tumor cells and provides supportive evidence to our result that baseline plasma EGFR-activating mutation status might serve as a predictive marker for the development of bone metastasis in NSCLC. Here, EGFR is linked to neoplasm.